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There is emerging evidence asserting the importance of orphan nuclear receptors 
(ONRs) in cancer initiation and progression. In breast cancer, there is a lot unknown 
about ONRs in terms of their expression profile and their transcriptional targets in the 
various stages of tumor progression. With the classification of breast tumors into distinct 
molecular subtypes, we assess ONR expression in the different breast cancer subtypes 
and with patient outcomes. Complementing this, we review evidence implicating ONR-
dependent molecular pathways in breast cancer progression to identify candidate ONRs 
as potential prognostic markers and/or as therapeutic targets.
Keywords: orphan nuclear receptors, breast cancer, transcription factors, breast cancer subtypes, small molecule 
inhibitors
introduction
Breast cancer is the most common cancer in women worldwide. Nearly 1.7 million new cases 
diagnosed in 2012 accounted for 12% of all new cancer cases and 25% of all cancers in women (1). 
The incidence of breast cancer is expected to increase primarily due to changes to the demographic 
with increasing aging populations and obesity, key risk factors for breast cancer. While patients with 
primary breast cancer are treated successfully, it is in the treatment of recurrent and invasive tumors 
where there is a clear need for the development of new therapies. Here, we discuss the potential of 
members of the nuclear receptor (NR) family as druggable targets for the discovery of new treat-
ments in breast cancer.
The growth of the primary tumor in the breast is predominantly dependent on estrogen (2), via its 
interaction with its target receptor, the estrogen receptor (ER), expressed in 75% of all breast cancers. 
Hence, endocrine therapy is currently the most effective adjuvant treatment for ER-positive breast 
cancer. These include selective ER modulators (SERMs), selective ER down-regulators (SERDs), and 
aromatase inhibitors (AIs) all of which target the estrogen action and biosynthesis pathways (3–5). 
Despite the success of endocrine treatments in breast cancer, patients often present with resistance to 
endocrine therapy, despite high tumor ER expression. Furthermore, approximately 70% of patients 
with advanced disease ultimately acquire resistance to endocrine therapy [reviewed by Musgrove and 
Sutherland (6)]. The mechanisms for de novo or acquired endocrine therapy resistance are still poorly 
understood and may involve mechanisms of crosstalk between ER and other cell signaling networks, 
e.g., the Human Epidermal Growth Factor Receptor (HER) pathways. The actions of ER, Progesterone 
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Receptor (PR), and Androgen Receptor (AR) in mediating breast 
cancer growth are well described in the literature. However, often 
overlooked in this context are the other members of the NR 
superfamily that function as transcription factors in regulating 
steroidogenesis, proliferation, and invasion and migration proper-
ties of cancer cells. The focus of the current review is to interrogate 
the expression patterns of the orphan nuclear receptors (ONR) 
and “adopted ONRs” in breast cancer, identify correlations with 
patient outcomes, and review the literature for functional evidence 
that may identify new ONRs as potentially linked to breast cancer 
in a prognostic sense or potential therapeutic targets.
Orphan NRs, referred to as ONRs throughout this review 
(Table 1), form a subgroup within the NR superfamily (7). Unlike 
the NRs, that are ligand activated; the ONRs have been classified 
together due to the lack of known endogenous ligands or other 
interacting synthetic compounds and drugs. Table  1 provides 
an overview of the ONR and adopted ONRs along with the 
potential endogenous or synthetic ligands that have been identi-
fied. While functioning in a similar manner to NRs, the ONRs 
can dimerize and bind to NR response elements (consisting of 
two palindromic NR half sites) to mediate transcription. As with 
NRs, ONRs can also hetero-dimerize, however it is ONRs that 
bind to NR half sites as monomers. Within the ONRs, the term 
“adopted ONRs” describes ONRs for which endogenous ligand 
or synthetic compounds have now been identified and shown to 
modulate activity (7–9) (Table  1). Structural analysis of ONRs 
also demonstrates that certain NRs, such as NR5A1 and NR5A2 
are held in a constitutively active confirmation to maintain 
ligand-independent activity (10–14). Furthermore, modulation 
of the activity of NRs and ONRs by co-regulator proteins such 
as Nuclear Receptor Co-activators (NCOAs 1–3, also termed 
steroid receptor co-activators or SRCs 1–3), form an essential 
component of functional modulation to dictate whether genes 
are actively transcribed or repressed (15–17). The identification 
of synthetic compounds to modulate ONR activity is testament 
to the druggability of this class of transcription factors making 
them an attractive target for drug development in cancer. Due to 
their druggability and wide-ranging cellular functions, there is 
considerable interest in identifying novel ligands for ONRs as a 
therapeutic tool.
Given the roles of ONRs in regulating transcription of genes 
involved in processes important for development, metabolism, 
immunity, angiogenesis, steroidogenesis, and fertility, their 
actions have also been implicated in multiple diseases including 
diverse types of cancers. Although not widely reported, there is 
emerging but clear evidence of ONR-dependent mechanisms 
in the regulation of tumor growth and progression. Recent 
work quantifying the expression profiles of the NR superfamily 
members in well curated tumor biopsy tissue and isolated cancer-
associated fibroblast (CAFs) now allow a good insight into the 
possible actions of NRs in the development and progression of 
breast cancer (55–57).
We analyzed datasets available online to establish correlations 
between ONR expression and clinical parameters that define 
breast cancer outcomes. We also present an overview of the cur-
rent understanding of ONR-related cellular mechanisms in breast 
cancer development.
Molecular Signatures Defining Breast 
Cancers
There are now several intrinsic molecular signatures acquired 
by genome-wide expression profiling of breast tumors that are 
used to stratify the heterogeneity of breast cancers (58–62). 
A clear delineation of these multi-gene signatures will ultimately 
allow personalized therapies. Breast tumors are classified into 
a variety of molecular subtypes with the four major subtypes 
being Luminal A, Luminal B, HER2-enriched, and basal-like 
tumors. Luminal A and Luminal B subtypes are both ER-positive 
tumors; Luminal A tumors being less aggressive than the Luminal 
B subtype, and more responsive to endocrine therapies (63–66). 
HER2-enriched tumors show amplification of the HER2 gene and 
these patients respond well to treatment that target HER2. High 
ER and PR levels, the lack of HER2 amplification in low-grade 
tumors and specific gene signatures, are now used as indicators 
of good effectiveness with endocrine therapy (61, 62). Basal-like 
tumors, also known as Triple-Negative Breast Cancers (TNBCs, 
lacking expression of ER, PR and HER2) are aggressive tumors 
with the only treatment options being surgery and chemotherapy.
In this vein, to address the question that other NRs could 
be used to further classify tumor subtypes, recently, three key 






NR0B1 DAX-1 Not known
NR0B2 SHP CD437 Retinoidsa (17–20)
NR1D1 Rev-Erbα Hemea (21–25)
NR1D2 Rev-Erbβ Hemea (21–25)
NR1F1 RORα Isoflavones, Cholesterol, derivatives (26–28)
NR1F2 RORβ all-trans retinoic acid (ATRA) (29)
NR1F3 RORγ Isoflavones (28)
NR2A1 HNF4α Fatty acids (30, 31)
NR2A2 HNF4γ Fatty acids (31)
NR2C1 TR2 Not known
NR2C2 TR4 Retinol/ATRAa (32)
NR2E1 TLX Ccrps: small molecule agonists (33)
NR2E3 PNR Benzimidazoles (34, 35)
NR2F1 COUP-TF-I Not known
NR2F2 COUP-TF-II Retinol/ATRAa (36)
NR2F6 EAR2 Not known
NR3B1 ERRα Isoflavones, Diethylstilbestrol (DES), 
Chlordane
(37–39)
NR3B2 ERRβ Isoflavones, DES, 4-Hydroxy tamoxifen 
(4HT)
(37, 38)
NR3B3 ERR gamma Isoflavones, DES, 4HT (37, 38, 40)
NR4A1 NGFI-B Cytosporone Ba, Diindolylmethane 
Analogs (C-DMIs)
(41–47)
NR4A2 NURR1 Benzimidazoles, C-DMIs, 
6-Mercaptopurine
(48–51)
NR4A3 NOR1 6-Mercaptopurine, Prostaglandin A2 (52, 53)
NR5A1 SF-1 Phospholipids (11, 12)
NR5A2 LRH-1 Phospholipids (11, 54)
NR6A1 GCNF Not known
aCompounds or proteins that bind the ONR.
Potential ligands are defined as those proposed to bind and modulate ONR 
transcriptional activity.
TABLe 2 | Correlation of ONR expression to DFS in breast cancer patients.
Gene symbol Common name As a whole Node pos Node neg LumA LumB Her2 pos Basal
NR0B1 DAX-1 ns ns ns ns ns ns ns
NR0B2 SHP ns ns p = 0.022# ns p = 0.004# ns ns
NR1D1 REV-ERB alpha ns ns ns ns p = 0.015* ns ns
NR1D2 REV-ERB beta ns ns ns ns ns ns p = 0.030#
NR1F1 ROR alpha ns ns ns ns ns ns ns
NR1F2 ROR beta ns ns ns ns p = 0.011# ns ns
NR1F3 ROR gamma ns ns ns ns ns ns ns
NR2A1 HNF4 alpha ns ns ns p = 0.035* ns ns ns
NR2A2 HNF4 gamma p = 0.001* ns ns ns ns ns p = 0.023*
NR2C1 TR2 ns ns ns ns p = 0.035* ns ns
NR2C2 TR4 ns ns ns ns ns ns ns
NR2E1 TLX ns ns ns ns p = 0.003# ns ns
NR2E3** PNR
NR2F1 COUP-TF-I ns ns ns ns ns ns ns
NR2F2 COUP-TF-II ns p = 0.009# ns ns ns ns ns
NR2F6 EAR2 ns ns ns p = 0.038# ns ns ns
NR3B1 ERR alpha p = 0.009* p = 0.019* ns ns ns ns ns
NR3B2 ERR beta ns ns p = 0.01# ns ns ns ns
NR3B3 ERR gamma ns p = 0.01# ns ns ns ns ns
NR4A1 NUR77 ns ns ns ns ns ns ns
NR4A2 NURR1 p = 0.003# p = 0.007# ns ns ns ns ns
NR4A3 NOR1 ns p = 0.003# ns ns ns ns ns
NR5A1 SF-1 ns ns ns ns p = 0.025# ns ns
NR5A2 LRH-1 ns ns ns ns p = 0.003* ns ns
NR6A1 GCNF ns ns p = 0.015# ns ns ns ns
Based on BreastMark mRNA analysis (http://glados.ucd.ie/BreastMark/mRNA_analysis.html).
Significance; p < 0.05, ns = non-significant; p ≥ 0.05.
#Higher ONR expression is significantly correlated with increased survival in BCa patients.
*Lower ONR expression is significantly correlated with increased survival in BCa patients.
**Not included in the database. DFS, disease free survival; BCa, breast cancer.
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studies provide a comprehensive expression profile of the NR 
superfamily and their interacting co-regulatory proteins in tumor 
and associated stroma in breast cancer (55–57). Based on these 
publications, akin to ER status, the expression of other NRs and 
ONRs could very likely provide additional prognostic power in 
the classification of breast tumor subtypes.
Correlation of ONR mRNA Transcript 
expression with Patient Survival Outcomes
We used publically available Kaplan–Meier Plotter1 and 
BreastMark2 algorithms to correlate ONR gene expression to 
clinical outcomes within the datasets available within the two 
platforms as indicated in Tables  2 and 3. Kaplan–Meier Plot 
analysis was used specifically to assess ONR expression in relation 
to relapse free survival (RFS) in breast cancer patients; analysis 
also stratified to ER-positive and ER-negative status from gene 
expression data and survival information of 1,809 patients collated 
from GEO (Affymetrix HGU133A and HGU133 Plus 2.0 micro-
arrays) EGA and TCGA databases (67). With the BreastMark 
algorithm, mRNA expression patterns of the genes of interest 
can be classified within breast cancer subtypes according to the 
PAM50 molecular signature (68). The database integrates gene 
1 www.kmplot.com
2 http://glados.ucd.ie/BreastMark/index.html
expression and survival data from 26 datasets from 12 microar-
ray platforms corresponding to 4,738 samples. We utilized the 
database to identify ONRs in which mRNA expression levels were 
positively or negatively correlated with disease progression in all 
breast cancer or stratified into the various subtypes.
ONRs Associated with the Luminal A Subtype
Lower expression of Hepatocyte Nuclear Factor 4 alpha (HNFα, 
NR2A1) and higher expression of V-erbA related protein (EAR2, 
NR2F6) were associated with increased DFS in patients with the 
Luminal A subtype of breast cancer (p = 0.035 and p = 0.038, 
respectively, Table 2). The functions of these two ONRs in the 
context of breast cancer are not defined as yet, although HNF4α, 
a key transcriptional regulator of hepatocyte differentiation and 
function in liver, acts as a tumor suppressor in the diethylini-
trosamine-induced rat model of liver carcinogenesis, and inhibits 
epithelial-mesenchymal transition (EMT) (69). In a recent study 
focusing on expression patterns of genes associated with altered 
metabolism of breast cancer cells (using the TCGA database), the 
analysis of 556 transcription factor sequence motifs identified 
HNF4α-specific response elements as enriched in differentially 
co-expressed gene targets (70). Interestingly, this data suggest a 
potential function for this ONR in breast cancer cells in mediat-
ing tumor proliferation via the regulation of cellular metabolism, 
and warrants further investigation.
EAR2 is a member of the COUP-TF orphan subfamily and 
its established functions include negative regulation of renin and 
TABLe 3 | Correlation of ONR expression to RFS in breast cancer patients.
Gene symbol Common name All BCa eR-positive BCa eR-negative BCa Affy iD
NR0B1 DAX-1 ns ns p = 0.0001# 206645_s_at
NR0B2 SHP p = 3.5e−7# ns ns 206410_at
NR1D1 REV-ERB alpha p = 9.1e−5# ns ns 31637_s_at
NR1D2 REV-ERB beta p = 1e−4* ns ns 209750_at
NR1F1 ROR alpha p = 0.004# ns ns 210426_x_at
NR1F2 ROR beta p = 0.0002# ns ns 206443_at
NR1F3 ROR gamma p = 0# p = 0.002# ns 206419_at
NR2A1 HNF4 alpha p = 2.9−5# ns ns 208429_x_at
NR2A2 HNF4 gamma p = 1.8e−6# ns ns 207456_at
NR2C1 TR2 ns ns ns 204791_at
NR2C2 TR4 p = 0.0036# ns ns 206038_s_at
NR2E1 TLX p = 0.0062# ns p = 0.0008# 207443_at
NR2E3 PNR ns p = 0.0036# ns 208385_at
NR2F1 COUP-TF-I p = 0.0029# ns ns 209506_s_at
NR2F2 COUP-TF-II ns ns p = 0.034* 209120_at
NR2F6 EAR2 ns ns ns 209262_s_at
NR3B1 ERR alpha ns ns ns 1487_at
NR3B2 ERR beta p = 2.2e−7# ns ns 207726_at
NR3B3** ERR gamma Not available
NR4A1 NUR77 p = 1.5e−5# p = 0.013# ns 202340_x_at
NR4A2 NURR1 p = 1.7e−8# p = 0.0054# ns 216248_s_at
NR4A3 NOR1 P = 0.0067# p = 0.014# ns 209959_at
NR5A1 SF-1 p = 0.046# ns ns 210333_at
NR5A2 LRH-1 p = 5.8e−12# ns ns 208337_s_at
NR6A1 GCNF p = 0.0003# ns ns 207742_s_at
Table is based on KM Plot per April 2015 (http://kmplot.com/analysis/index.php?p=service&cancer=breast).
Significance; p < 0.05, ns = non-significant; p ≥ 0.05
#Higher ONR expression is significantly correlated with increased survival in BCa patients.
*Lower ONR expression is significantly correlated with increased survival in BCa patients.
**Not included in the database. RFS, relapse free survival; BCa, breast cancer.
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the luteinizing hormone receptor gene transcription and brain 
function including memory and learning (71–74). EAR2 expres-
sion is highly expressed in both ER-positive and ER-negative 
tumors relative to normal breast tissue (57). Additionally, EAR2 
has been shown to directly interact with the aromatase promoter 
and down-regulate the expression of aromatase in breast cancer 
cell lines (75).
ONRs Associated with the Luminal B Subtype
Within the BreastMark criteria, reduced expression of REV-ERBα, 
TR2, LRH-1, and increased RORβ and SHP expression are signifi-
cantly associated with greater DFS in patients in Luminal B tumors 
(p = 0.015, p = 0.035, p = 0.003, p = 0.011, p = 0.004, p = 0.025 
and p =  0.003, respectively, Table 2). In contrast to Luminal A 
tumors, a greater number ONRs are associated with the Luminal 
B subtype, a more aggressive tumor and patients are often resist-
ant to treatment. The functional implications of these expression 
profiles for each ONR associations are discussed in detail below.
REV-ERBα (also known as NR1D1) is a transcriptional repres-
sor, abundantly expressed in adipose tissue and its functions 
are linked mainly to adipocyte differentiation, regulation of cell 
metabolism, and thermogenic responses (76) REV-ERBα lacks a 
transcriptional activation domain and represses target genes via its 
interaction with the transcriptional corepressor N-CoR. REV-ERBα 
has been shown to have a prosurvival function in HER2-positive 
breast cancer cells (77). However, recently it has been shown that 
REV-ERBβ (NR1D2) is also expressed in breast cancer cell lines 
and that its expression not correlated with HER2 or ER expression 
(9). Furthermore, the identification of a novel REV-ERBβ inhibitor, 
ARN5187, results in tumor cell cytotoxicity suggesting anticancer 
effects of REV-ERBβ suppression (9). We observed higher expres-
sion of REV-ERBβ as significantly associated with increased DFS 
in the basal cancer subtype (p = 0.03). Further determination of 
the protein expression and function of the two REV-ERB isoforms 
would allow a better understanding of the roles these ONRs play 
in the different breast cancer subtypes particularly with regards to 
HER2 status. Given its significant interaction with multiple co-
regulators in ER-negative breast tumors, and a significant correla-
tion to predict poorer outcome for patients, further investigation of 
the two REV-ERB isoforms in breast cancer is warranted.
Similarly to REV-ERB isoforms, TR2 (NR2C1) is a transcrip-
tional repressor, and inhibits ERα-mediated transcription to 
regulate cell proliferation in breast cancer cells (78). In transgenic 
mouse models where TR2 is either over-expressed or down 
regulated, TR2 was identified as a key transcriptional repres-
sor of GATA1 (79). Therefore, reduced TR2 in tumors may be 
the mechanism via which increased GATA1 promotes a more 
aggressive tumor phenotype in breast cancers (80). However, it 
is the lower expression of TR2 that was associated with increased 
survival in women with Luminal B tumors (Table 2, p = 0.035). 
Further investigation of the protein localization and correlation 
to TR2 mRNA expression profiles and the identification of breast 
cancer specific gene targets are required to further understand this 
observation.
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In contrast to the REV-ERBs and TR2, Liver Receptor 
Homolog-1 (LRH-1, NR5A2) is a constitutive transcriptional 
activator, binding DNA as a monomer to promote transcription 
(11, 12, 14). The activity of LRH-1 was previously thought to be 
mainly under the control of co-regulators (14, 54, 81, 82, 83); 
however potential endogenous ligands identified include phos-
phatidylinositols, in particular, phosphatidylinositol-3-phosphate 
(PIP3) (11, 54), small molecule agonists (84) and antagonists (85).
Low LRH-1 expression significantly correlated with increased 
DFS in Luminal B tumor patients (Table 2, p = 0.003). Additionally, 
a strong correlation with co-regulator expression in ER-negative 
breast tumors suggests that increased LRH-1 activity may cor-
relate with predicted poorer outcome for those patients (55). The 
expression of LRH-1 in both ER-positive and ER-negative tumors 
indicate that more functional evidence is require to determine 
its contribution in these varying tumor contexts. There is strong 
functional evidence linking LRH-1 to estrogen-regulated path-
ways in breast cancer tumor and associated stromal cell types 
[reviewed in Ref. (86)].
LRH-1 stimulates transcription of the aromatase gene, thereby 
promoting estrogen synthesis within CAFs (87–89). Given this 
strong association with tumor-associated estrogen production, 
most functional studies have been directed toward understanding 
the interplay between LRH-1 and estrogen-dependent prolif-
eration pathways within breast tumors. While LRH-1 expression 
itself is under estrogen regulation, LRH-1 in a positive feedback 
manner induces estrogen-mediated cell proliferation (90). This 
is primarily via the co-operative regulation of gene-transcription 
of ERα and LRH-1 target genes (91–93). Both ERα and LRH-1 
directly stimulate the transcription of one another, adding to 
the close functional relationship between the two NRs (90, 
94). There are five transcript variants of LRH-1 that give rise to 
protein isoforms of three different sizes. There is some evidence 
that transcript variant four may be the active LRH-1 isoform in 
ER-positive breast cancer cells (94).
LRH-1 expression is detectable in both ER-positive and negative 
tumors (95). Despite low mRNA, LRH-1 protein levels are readily 
detected in ER-negative breast cancer cell lines and tumor tissue 
(56, 95–97) and this discrepancy is partly explained by increased 
transcript stability in ER-negative tumor cells (97). Knockdown 
of LRH-1 expression with shRNA constructs in ER-negative cells 
reduced cell migration and invasion in ER-negative breast cancer 
cells (98). The functional importance of LRH-1 in ER-negative 
cells and the ability of LRH-1 to regulate cell proliferation gene 
expression in endocrine-resistant breast cancer cells (91) as well as 
in the presence of SERDs (92) suggests a possible role in promot-
ing tumor-aggressiveness. Given the breadth of knowledge on the 
tumor promoting effects of LRH-1 in various cancers, LRH-1 is a 
strong candidate as a therapeutic target. However, there is a need 
to demonstrate its contribution to mammary tumor initiation 
and formation using in vivo mouse models.
As age is the most common risk factor in breast cancer, it is 
interesting to note that the expression of RAR-related orphan 
receptor β (RORβ, also known as NR1F2) is greater in the post-
menopausal breast compared to premenopausal tissue. However, 
its expression is significantly downregulated in ER-negative 
breast cancer implicating a potential role in the early stages of 
tumor growth (57). Above median expression of RORβ is cor-
related with greater DFS rates in patients with Luminal B cancers 
(Table 2, p = 0.011). Although its function is unclear, the ligands 
for RORβ may provide additional functional evidence of its roles 
in breast cancer cells.
ONRs Associated with Lymph Node-Positive 
Breast Cancer
Lymph node status is one of the most important predictors of 
breast cancer recurrence and survival. Data from the Surveillance, 
Epidemiology, and End Results (SEER) Program shows that 
women with lymph node negative tumors have a better prognosis 
compared to those with tumors in the lymph nodes.
In addition to overall DFS for all breast cancer cases, low 
ERRα and high NURR1 expression was associated with improved 
survival in patients with lymph node positive tumors (p = 0.019 
and p = 0.007, respectively, Table 2). Structurally and function-
ally related to the ERs, ERRα (Estrogen-related receptor (ERR) 
alpha, also known as NR3B1) over-expression is associated with 
a poorer outcome in patients with ER-negative breast cancer (99). 
Functional in vitro studies in breast cancer cell lines show that the 
suppression of ERRα inhibits cellular proliferation and migration 
(100). Expression of ERRα positively correlates with HER2 status 
in breast tumors and ERRα transcriptional activity is positively 
modulated by EGFR/HER2 signaling in breast cancer cells. 
This suggests a role for ERRα in mediating the transition from 
ER-positive luminal toward more aggressive HER2-expressing 
tumor subtype (101, 102).
NURR1 (the NR-related 1 protein, also known as NR4A2), 
nerve growth factor I B (NGFIB, also known as Nur77 or NR4A1), 
and the neuron-derived orphan receptor 1 (NOR1, NR4A3) 
together constitute the NR4A subfamily of NRs (103–105). No 
endogenous ligands have been identified for these ONRs and 
their ability to transactivate genes appears to be constitutive. The 
NR4A receptors are however targeted by several hormones and 
xenobiotic compounds that affect the expression and/or activity 
of these stress early response genes (Table 1) (106). A recent study 
profiling all NRs in ER-positive and ER-negative breast tumors 
revealed that while most NR mRNA levels were significantly 
lower in breast cancer versus normal tissue, the expression of 
all of the NR4A family members (Nur77, NURR1, and NOR1) 
were significantly up-regulated in ER-positive breast cancer (57). 
Additionally in ER-negative breast tumors, when compared to 
normal breast tissue, NUR77 and NOR-1, together with EAR2, 
were found to have significantly increased (57).
In primary tumors, protein levels of NURR1 are inversely 
correlated with lymph node metastasis (107). This observation 
is mirrored in our analysis with the BreastMark dataset showing 
increased NURR1 mRNA expression is significantly correlated 
with increased survival in lymph node positive breast cancer. 
Data analysis from BreastMark and Kaplan–Meier Plotter indi-
cate above median expression of NURR1 mRNA is associated 
with better prognosis and RFS in all breast cancer patients (107). 
However, functional in  vivo experiments indicate the contrary. 
When NURR1 expression is knocked down by shRNA, growth of 
xenografts of highly invasive MDA-MB-231 and MDA-MB-468 
breast cancer cells in athymic nude mice is significantly attenuated 
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(107). Interestingly, high cytoplasmic expression of NURR1 is sig-
nificantly correlated with advanced pathologic stage and higher 
tumor grade of bladder tumors as well as an increased number of 
distant metastases and decreased recurrence free survival (108). 
Thus, not only the expression level of NURR1 but the sub-cellular 
localization in which it is expressed may be of importance in its 
contribution toward tumor growth and metastatic potential.
Increased expression of NOR1 is correlated with better clini-
cal outcomes in patients with lymph node positive tumors and 
ER-positive tumors (p =  0.003 and p =  0.014 Tables  2 and 3, 
respectively). Little is known about the actions of NOR1 in breast 
cancer, however in the ER-positive breast cancer cell line MCF7, 
NOR1 mRNA is up-regulated by a pro-apoptotic compound 
A23187 (109), shown to cause apoptotic cell death, suggesting 
a possible role in tumor cell apoptosis. NOR1 and NUR77 are 
thought to form heterodimers with NR retinoid X receptor RXR 
to modulate retinoic acid (RA) signaling (110, 111). Additionally 
in a positive feedback loop, RAs are involved in the positive regula-
tion of NOR1 and NURR1 and the downregulation of NUR77 in 
breast cancer cells (112) correlating to decrease cell proliferation 
(113–115). Taken together these studies indicate that the NR4A 
family members may exert multiple functions in cancer, through 
their genomic functions in promoting tumor growth and survival, 
and, paradoxically, through non-genomic functions that may 
potentially exert tumor suppression by induction of apoptosis.
We observed an association of increased COUP-TFII expres-
sion with improved survival in patients with lymph node-positive 
tumors (Table 2 , p = 0.009). The mRNA levels of the COUP tran-
scription factors COUP-TFI (NR2F1) and COUP-TFII (NR2F2) 
were reported to be significantly decreased in both ER-positive 
and ER-negative breast cancer tissue compared to normal breast 
(57). COUP-TFII mRNA showed a discriminating role in the clas-
sification of breast cancer grades as it was more highly expressed 
in better-differentiated, lower-grade lesions (57). COUP-TFII was, 
in addition to the NR members TRβ, MR and PPARγ, reported to 
be a predictor of improved metastasis-free survival in tamoxifen-
treated patients after adjustment for expression of ERα (57).
However, previously the amounts of protein of both these 
receptors have been reported to be higher in human breast 
cancer tissue than normal breast (116, 117). While the results are 
uncertain for COUP-TFI as it was only examined in a very small 
set of samples (116), COUP-TFII protein expression has been 
examined in a larger cohort of human breast cancers (117). Of 
119 invasive ductal carcinoma of the breast, 59% stained positive 
for COUP-TFII in the nuclei of carcinoma cells (117). Higher 
nuclear expression of COUP-TFII was correlated with decreased 
disease-free and overall survival of the patient (117). Additionally, 
COUP-TFII was correlated to clinical stage (significantly higher 
expressed in stage IV tumors than stage I), histological grade 
(significantly higher expression with grade) and ERα status (sig-
nificantly higher expressed in ERα positive than negative breast 
carcinomas) (117). Several groups have looked at the function of 
COUP-TFI and COUP-TFII in breast cancer cell lines. COUP-
TFI may promote estrogen-independent transcriptional activity 
of ERα in breast cancer cells (116, 118). Furthermore, COUP-TFI 
mediates its actions through CXCL12/CXCR4 signaling. The 
over-expression of COUP-TFI results in down-regulation of 
CXCL12 and up-regulation of CXCR4 expression, to promote 
motility of MCF-7 cells (119). Furthermore, COUP-TFI mRNA 
expression is significantly higher in grade 1 (but not in grade 2 or 
3) tumors than in normal breast tissue and that CXCR4 mRNA 
is significantly higher in cancerous tissue than in normal breast 
tissue and its expression is increasing with tumor grade, whereas 
transcripts of CXCL12 was significantly decreased in all the 
tumor grades compared to normal tissues (119).
ONRs Associated with Lymph Node-Negative 
Breast Cancer
Higher SHP, ERRβ and GCNF expression were associated with 
improved survival in patients with lymph node-negative tumors 
(p = 0.022, p = 0.01, p = 0.015, respectively, Table 2). Like Dax-1 
(NROB1), the other member of this subgroup, short heterodimer 
partner (SHP, also termed NROB2) lacks a DNA-binding domain 
(DBD) and represses the action of NRs, including ERα through 
direct interaction with the receptor (120). SHP has been shown 
to inhibit aromatase expression by repressing LRH-1 activity on 
the promoter II element of Cyp19, the gene encoding aromatase 
(121). The actions of SHP in the repression of ER, LRH-1 and other 
NRs illustrates the importance of assessing the expression profile 
of this ONR in relation to other NRs to gage NR functionality. 
Above median expression of SHP also correlated with increased 
DFS in the luminal B subtype (Table 2 , p = 0.004). These findings 
indicate that SHP may have a protective function in breast cancers 
and may be specifically so in lymph node-negative and luminal 
B subtype tumors. The expression and further characterization 
of this ONR are important due to its interactions with a range 
of NRs; whether SHP binds preferentially to ONRs over other 
co-regulators would also assist in defining its contribution to 
ONR-dependent actions in the cancer context.
Estrogen-related receptors are a subgroup of ONRs that have a 
strong homology with ER. We have previously discussed the roles 
of ERRα in lymph node positive tumors. Above median expres-
sion of ERRα is associated with greater survival in patients with 
lymph node-negative tumors. In other studies, the overexpression 
of ERRβ has been correlated with improved prognosis and longer 
relapse-free survival in breast cancer patients, and its mRNA levels 
inversely correlated with tumor cells in S-phase in patient-derived 
tumor samples (122). The functions of ERRs are tightly related to 
ER-mediated actions in breast cancer cells mainly due to the high 
degree of structural similarity to one another and to ER (123, 124), 
there is very little known about the details of ERR family members 
in this context. Recently though, in a detailed comparison of the 
ERRs on estradiol-stimulated ER transcription it was identified 
that it is only ERRβ that co-localized into the nucleus with ERα 
and with fluorescence resonance energy transfer revealed that 
ERRβ directly interacted with ERα to repress its transcriptional 
activity (125). The findings further suggest a unique inhibitory 
role for ERRβ in estrogen-dependent cellular function such as 
cancer cell proliferation via the regulation of cell cycle progression.
Similarly above median expression of Germ Cell Nuclear 
Factor Receptor (GCNF) is correlated with improved patient 
outcomes compared to those with below median expression 
(Table 2, p = 0.015). Initially identified as exclusively expressed 
in germ cells (126), GCNF is well characterized for its importance 
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in embryonic development in regulating neural development and 
gastrulation (127) and oocyte function (128). Its unlikely role in 
breast cancer is suggested from a recent analysis of Affymetrix, 
Illumina and RNAseq microarray data to perform gene enrich-
ment analysis identified shared common promoter motifs for 
GNCF in TNBC samples (129).
ONRs in eR-Positive and eR-Negative 
Breast Cancer
The Kaplan–Meier Plot analysis was used to assess ONR expression in 
relation to RFS in breast cancer patients; stratified to ER-positive and 
ER-negative tumors. Here, gene expression data and survival infor-
mation of 1,809 patients have been collated from GEO (Affymetrix 
HGU133A and HGU133 + 2 microarrays) EGA and TCGA (130). 
Above median expression of 16 out of 24 ONRs was significantly cor-
related with increased RFS when analyzing all breast cancer patients 
in the database (Table 3, n = 3554). As an exception, lower expression 
of REV-ERBβ was correlated with increased patient RFS (p = 1.0e−4). 
In ER-positive breast cancer, above median expression of five ONRs 
including RORγ, PNR, Nurr77, Nurr1 and NOR1 was associated 
with better RFS (p = 0.002, p = 0.0036, p = 0.013, p = 0.0054 and 
p = 0.014, respectively, Table 3). In ER-negative breast cancer patients, 
higher expression of Dax-1 and TLX, and lower COUP-TFII expres-
sion were found to significantly correlate with increased RFS of 
(p = 0.0001, p = 0.0008, and p = 0.034, respectively, Table 3). This 
pattern or  association with ER status may be important in identifying 
the  regulatory mechanisms via which these ONRs are expressed; 
whether these ONRs modify/enhance the responses to endocrine 
therapies directed at ER such as SERMs are yet to be delineated.
Summary
The NR family of transcription factors plays diverse and impor-
tant roles in development and the regulation of normal physi-
ological functions in a tissue-specific manner. By understanding 
the contribution of ONRs in breast cancer subtypes, many novel 
mechanistic insights into tumor progression can be gleaned. 
From our data analysis, we observe complex expression patterns 
of various ONRs that could be selectively assessed in Luminal A, 
Luminal B, Lymph node positive and negative tumor types. Indeed 
within the specific subtype, the function of a particular ONR may 
possess a completely unique transcriptional imprint, therefore 
with varied effects on tumor proliferation and invasiveness; as 
is observed for AR, which can have pro- and anti-proliferative 
effects that is dependent on ER status of the breast cancer cell.
There is a lot that is unknown about ONRs in terms of their 
basic expression profile, mode of regulation of expression, cell 
subtype expression patterns, roles in normal mammary gland 
development processes, and transcriptional targets in the mam-
mary gland and tumor scenarios. Our review attempted to iden-
tify “candidates” that were closely associated with breast cancer 
survival outcomes and whether molecular subtypes of breast 
cancer could be linked to ONR expression patterns. In addition 
to expression patterns, large-scale ChIP-seq experiments in well 
defined in breast cancer tissue samples and in in  vivo tumor 
models will identify ONRs that are critical in this process. In 
addition, determining changes in ONR expression linked to key 
risk factors in breast cancer may also assist in understanding the 
mechanisms of this disease. The ligand-dependent actions of NRs 
provide extensive information that could potentially allow us to 
design new ligands for the ONRs in order to modulate their func-
tion. By the pharmacological targeting critical ONRs, we may in 
future identify effective therapies that could complement existing 
therapies in the treatment of breast cancer.
Acknowledgments
We acknowledge the support of Victorian Government’s Opera-
tional Infrastructure Support Program and the National Health 
and Medical Research Council of Australia Grants. ALC is sup-
ported by an NHMRC Career Development Award (ID 1062247).
References
 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et  al. 
Cancer incidence and mortality worldwide: sources, methods and major pat-
terns in GLOBOCAN 2012. Int J Cancer (2015) 136:E359–86. doi:10.1002/
ijc.29210 
 2. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, 
androgen, and progesterone concentrations and breast cancer risk among 
postmenopausal women. J Natl Cancer Inst (2004) 96:1856–65. doi:10.1093/
jnci/djh336 
 3. Brodie AM, Dowsett M, Coombes RC. Aromatase inhibitors as new 
endocrine therapy for breast cancer. Cancer Treat Res (1988) 39:51–65. 
doi:10.1007/978-1-4613-1731-9_4 
 4. Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor transcription 
and transactivation: estrogen receptor alpha and estrogen receptor beta: reg-
ulation by selective estrogen receptor modulators and importance in breast 
cancer. Breast Cancer Res (2000) 2:335–44. doi:10.1186/bcr78 
 5. Simpson ER, Dowsett M. Aromatase and its inhibitors: significance for 
breast cancer therapy. Recent Prog Horm Res (2002) 57:317–38. doi:10.1210/
rp.57.1.317 
 6. Musgrove EA, Sutherland RL. Biological determinants of endocrine 
resistance in breast cancer. Nat Rev Cancer (2009) 9:631–43. doi:10.1038/
nrc2713 
 7. Benoit G, Cooney A, Giguere V, Ingraham H, Lazar M, Muscat G, et  al. 
International union of pharmacology. LXVI. Orphan nuclear receptors. 
Pharmacol Rev (2006) 58:798–836. doi:10.1124/pr.58.4.10 
 8. Chen T. Nuclear receptor drug discovery. Curr Opin Chem Biol (2008) 
12:418–26. doi:10.1016/j.cbpa.2008.07.001 
 9. De Mei C, Ercolani L, Parodi C, Veronesi M, Vecchio CL, Bottegoni G, 
et al. Dual inhibition of REV-ERBbeta and autophagy as a novel pharma-
cological approach to induce cytotoxicity in cancer cells. Oncogene (2015) 
34(20):2597–608. doi:10.1038/onc.2014.203 
 10. Benoit G, Malewicz M, Perlmann T. Digging deep into the pockets of orphan 
nuclear receptors: insights from structural studies. Trends Cell Biol (2004) 
14:369–76. doi:10.1016/j.tcb.2004.05.007 
 11. Krylova IN, Sablin EP, Moore J, Xu RX, Waitt GM, MacKay JA, et  al. 
Structural analyses reveal phosphatidyl inositols as ligands for the NR5 
orphan receptors SF-1 and LRH-1. Cell (2005) 120:343–55. doi:10.1016/j.
cell.2005.01.024 
 12. Li Y, Choi M, Cavey G, Daugherty J, Suino K, Kovach A, et al. Crystallographic 
identification and functional characterization of phospholipids as ligands 
for the orphan nuclear receptor steroidogenic factor-1. Mol Cell (2005) 
17:491–502. doi:10.1016/j.molcel.2005.02.002 
 13. Li Y, Lambert MH, Xu HE. Activation of nuclear receptors: a perspective 
from structural genomics. Structure (2003) 11:741–6. doi:10.1016/
S0969-2126(03)00133-3 
August 2015 | Volume 6 | Article 1158
Aesoy et al. Orphan nuclear receptors and breast cancer
Frontiers in Endocrinology | www.frontiersin.org
 14. Sablin EP, Krylova IN, Fletterick RJ, Ingraham HA. Structural basis for 
ligand-independent activation of the orphan nuclear receptor LRH-1. Mol 
Cell (2003) 11:1575–85. doi:10.1016/S1097-2765(03)00236-3 
 15. Lahusen T, Henke RT, Kagan BL, Wellstein A, Riegel AT. The role and regula-
tion of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer 
Res Treat (2009) 116:225–37. doi:10.1007/s10549-009-0405-2 
 16. Oh AS, Lahusen JT, Chien CD, Fereshteh MP, Zhang X, Dakshanamurthy 
S, et al. Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/
SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells. 
Mol Cell Biol (2008) 28:6580–93. doi:10.1128/MCB.00118-08 
 17. Dawson MI, Xia Z, Jiang T, Ye M, Fontana JA, Farhana L, et al. Adamantyl-
substituted retinoid-derived molecules that interact with the orphan nuclear 
receptor small heterodimer partner: effects of replacing the 1-adamantyl or 
hydroxyl group on inhibition of cancer cell growth, induction of cancer cell 
apoptosis, and inhibition of SRC homology 2 domain-containing protein 
tyrosine phosphatase-2 activity. J Med Chem (2008) 51:5650–62. doi:10.1021/
jm800456k 
 18. Dawson MI, Xia Z, Liu G, Ye M, Fontana JA, Farhana L, et al. An adaman-
tyl-substituted retinoid-derived molecule that inhibits cancer cell growth and 
angiogenesis by inducing apoptosis and binds to small heterodimer partner 
nuclear receptor: effects of modifying its carboxylate group on apoptosis, 
proliferation, and protein-tyrosine phosphatase activity. J Med Chem (2007) 
51(18):2622–39. doi:10.1021/jm800456k 
 19. Farhana L, Dawson MI, Dannenberg JH, Xu L, Fontana JA. SHP and Sin3A 
expression are essential for adamantyl-substituted retinoid-related mole-
cule-mediated nuclear factor-kappaB activation, c-Fos/c-Jun expression, 
and cellular apoptosis. Mol Cancer Ther (2009) 8:1625–35. doi:10.1158/1535-
7163.MCT-08-0964 
 20. Farhana L, Dawson MI, Leid M, Wang L, Moore DD, Liu G, et  al. 
Adamantyl-substituted retinoid-related molecules bind small heterodimer 
partner and modulate the Sin3A repressor. Cancer Res (2007) 67:318–25. 
doi:10.1158/0008-5472.CAN-06-2164 
 21. Kojetin D, Wang Y, Kamenecka TM, Burris TP. Identification of SR8278, a 
synthetic antagonist of the nuclear heme receptor REV-ERB. ACS Chem Biol 
(2011) 6:131–4. doi:10.1021/cb1002575 
 22. Kumar N, Solt LA, Wang Y, Rogers PM, Bhattacharyya G, Kamenecka TM, 
et al. Regulation of adipogenesis by natural and synthetic REV-ERB ligands. 
Endocrinology (2010) 151:3015–25. doi:10.1210/en.2009-0800 
 23. Raghuram S, Stayrook KR, Huang P, Rogers PM, Nosie AK, McClure DB, 
et al. Identification of heme as the ligand for the orphan nuclear receptors 
REV-ERBalpha and REV-ERBbeta. Nat Struct Mol Biol (2007) 14:1207–13. 
doi:10.1038/nsmb1344 
 24. Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, et  al. 
Regulation of circadian behaviour and metabolism by synthetic REV-ERB 
agonists. Nature (2012) 485:62–8. doi:10.1038/nature11030 
 25. Yin L, Wu N, Curtin JC, Qatanani M, Szwergold NR, Reid RA, et al. Rev-
erbalpha, a heme sensor that coordinates metabolic and circadian pathways. 
Science (2007) 318:1786–9. doi:10.1126/science.1150179 
 26. Kallen J, Schlaeppi JM, Bitsch F, Delhon I, Fournier B. Crystal structure of the 
human RORalpha ligand binding domain in complex with cholesterol sulfate 
at 2.2 A. J Biol Chem (2004) 279:14033–8. doi:10.1074/jbc.M400302200 
 27. Kallen JA, Schlaeppi JM, Bitsch F, Geisse S, Geiser M, Delhon I, et al. X-ray 
structure of the hRORalpha LBD at 1.63 A: structural and functional data 
that cholesterol or a cholesterol derivative is the natural ligand of RORalpha. 
Structure (2002) 10:1697–707. doi:10.1016/S0969-2126(02)00912-7 
 28. Kojima H, Takeda Y, Muromoto R, Takahashi M, Hirao T, Takeuchi S, et al. 
Isoflavones enhance interleukin-17 gene expression via retinoic acid recep-
tor-related orphan receptors alpha and gamma. Toxicology (2015) 329:32–9. 
doi:10.1016/j.tox.2015.01.007 
 29. Stehlin-Gaon C, Willmann D, Zeyer D, Sanglier S, Van Dorsselaer A, Renaud 
JP, et al. All-trans retinoic acid is a ligand for the orphan nuclear receptor 
ROR beta. Nat Struct Biol (2003) 10:820–5. doi:10.1038/nsb979 
 30. Hertz R, Magenheim J, Berman I, Bar-Tana J. Fatty acyl-CoA thioesters 
are ligands of hepatic nuclear factor-4alpha. Nature (1998) 392:512–6. 
doi:10.1038/33185 
 31. Wisely GB, Miller AB, Davis RG, Thornquest AD Jr, Johnson R, Spitzer T, et al. 
Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds 
fatty acids. Structure (2002) 10:1225–34. doi:10.1016/S0969-2126(02)00829-8 
 32. Zhou XE, Suino-Powell KM, Xu Y, Chan CW, Tanabe O, Kruse SW, et al. The 
orphan nuclear receptor TR4 is a vitamin A-activated nuclear receptor. J Biol 
Chem (2011) 286:2877–85. doi:10.1074/jbc.M110.168740 
 33. Benod C, Villagomez R, Filgueira CS, Hwang PK, Leonard PG, Poncet-
Montange G, et  al. The human orphan nuclear receptor tailless (TLX, 
NR2E1) is druggable. PLoS One (2014) 9:e99440. doi:10.1371/journal.
pone.0099440 
 34. Qin Q, Knapinska A, Dobri N, Madoux F, Chase P, Hodder P, et al. In pursuit of 
synthetic modulators for the orphan retina-specific nuclear receptor NR2E3. 
J Ocul Pharmacol Ther (2013) 29:298–309. doi:10.1089/jop.2012.0135 
 35. Wolkenberg SE, Zhao Z, Kapitskaya M, Webber AL, Petrukhin K, Tang 
YS, et al. Identification of potent agonists of photoreceptor-specific nuclear 
receptor (NR2E3) and preparation of a radioligand. Bioorg Med Chem Lett 
(2006) 16:5001–4. doi:10.1016/j.bmcl.2006.07.056 
 36. Kruse SW, Suino-Powell K, Zhou XE, Kretschman JE, Reynolds R, Vonrhein 
C, et al. Identification of COUP-TFII orphan nuclear receptor as a retinoic 
acid-activated receptor. PLoS Biol (2008) 6:e227. doi:10.1371/journal.
pbio.0060227 
 37. Coward P, Lee D, Hull MV, Lehmann JM. 4-Hydroxytamoxifen binds to and 
deactivates the estrogen-related receptor gamma. Proc Natl Acad Sci U S A 
(2001) 98:8880–4. doi:10.1073/pnas.151244398 
 38. Suetsugi M, Su L, Karlsberg K, Yuan YC, Chen S. Flavone and isoflavone 
phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res 
(2003) 1(13):981–91. 
 39. Yang C, Chen S. Two organochlorine pesticides, toxaphene and chlordane, 
are antagonists for estrogen-related receptor alpha-1 orphan receptor. Cancer 
Res (1999) 59:4519–24. 
 40. Greschik H, Flaig R, Renaud JP, Moras D. Structural basis for the deac-
tivation of the estrogen-related receptor gamma by diethylstilbestrol or 
4- hydroxytamoxifen and determinants of selectivity. J Biol Chem (2004) 
279:33639–46. doi:10.1074/jbc.M402195200 
 41. Chintharlapalli S, Burghardt R, Papineni S, Ramaiah S, Yoon K, Safe S. 
Activation of Nur77 by selected 1,1-Bis(3’-indolyl)-1-(p-substituted phenyl)
methanes induces apoptosis through nuclear pathways. J Biol Chem (2005) 
280:24903–14. doi:10.1074/jbc.M500107200 
 42. Cho SD, Lee SO, Chintharlapalli S, Abdelrahim M, Khan S, Yoon K, 
et  al. Activation of nerve growth factor-induced B alpha by methylene- 
substituted diindolylmethanes in bladder cancer cells induces apoptosis 
and inhibits tumor growth. Mol Pharmacol (2010) 77:396–404. doi:10.1124/
mol.109.061143 
 43. Cho SD, Lei P, Abdelrahim M, Yoon K, Liu S, Guo J, et al. 1,1-bis(3’-indo-
lyl)-1-(p-methoxyphenyl)methane activates Nur77-independent proapop-
totic responses in colon cancer cells. Mol Carcinog (2008) 47:252–63. 
doi:10.1002/mc.20378 
 44. Cho SD, Yoon K, Chintharlapalli S, Abdelrahim M, Lei P, Hamilton S, et al. 
Nur77 agonists induce proapoptotic genes and responses in colon cancer cells 
through nuclear receptor-dependent and nuclear receptor-independent path-
ways. Cancer Res (2007) 67:674–83. doi:10.1158/0008-5472.CAN-06-2907 
 45. Lee SO, Abdelrahim M, Yoon K, Chintharlapalli S, Papineni S, Kim K, 
et  al. Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits 
pancreatic cancer cell and tumor growth. Cancer Res (2010) 70:6824–36. 
doi:10.1158/0008-5472.CAN-10-1992 
 46. Liu JJ, Zeng HN, Zhang LR, Zhan YY, Chen Y, Wang Y, et  al. A unique 
pharmacophore for activation of the nuclear orphan receptor Nur77 
in vivo and in vitro. Cancer Res (2010) 70:3628–37. doi:10.1158/0008-5472.
CAN-09-3160 
 47. Zhan Y, Du X, Chen H, Liu J, Zhao B, Huang D, et al. Cytosporone B is an 
agonist for nuclear orphan receptor Nur77. Nat Chem Biol (2008) 4:548–56. 
doi:10.1038/nchembio.106 
 48. Dubois C, Hengerer B, Mattes H. Identification of a potent agonist of the 
orphan nuclear receptor Nurr1. ChemMedChem (2006) 1:955–8. doi:10.1002/
cmdc.200600078 
 49. Hintermann S, Chiesi M, von Krosigk U, Mathe D, Felber R, Hengerer 
B. Identification of a series of highly potent activators of the Nurr1 
signaling pathway. Bioorg Med Chem Lett (2007) 17:193–6. doi:10.1016/j.
bmcl.2006.09.062 
 50. Inamoto T, Papineni S, Chintharlapalli S, Cho SD, Safe S, Kamat AM. 
1,1-Bis(3’-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear 
August 2015 | Volume 6 | Article 1159
Aesoy et al. Orphan nuclear receptors and breast cancer
Frontiers in Endocrinology | www.frontiersin.org
receptor Nurr1 and inhibits bladder cancer growth. Mol Cancer Ther (2008) 
7:3825–33. doi:10.1158/1535-7163.MCT-08-0730 
 51. Ordentlich P, Yan Y, Zhou S, Heyman RA. Identification of the antineoplastic 
agent 6-mercaptopurine as an activator of the orphan nuclear hormone recep-
tor Nurr1. J Biol Chem (2003) 278:24791–9. doi:10.1074/jbc.M302167200 
 52. Kagaya S, Ohkura N, Tsukada T, Miyagawa M, Sugita Y, Tsujimoto G, et al. 
Prostaglandin A2 acts as a transactivator for NOR1 (NR4A3) within the 
nuclear receptor superfamily. Biol Pharm Bull (2005) 28:1603–7. doi:10.1248/
bpb.28.1603 
 53. Wansa KD, Harris JM, Yan G, Ordentlich P, Muscat GE. The AF-1 domain 
of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator 
recruitment, and activation by the purine anti-metabolite 6-mercaptopurine. 
J Biol Chem (2003) 278:24776–90. doi:10.1074/jbc.M300088200 
 54. Ortlund EA, Lee Y, Solomon IH, Hager JM, Safi R, Choi Y, et al. Modulation 
of human nuclear receptor LRH-1 activity by phospholipids and SHP. Nat 
Struct Mol Biol (2005) 12:357–63. doi:10.1038/nsmb910 
 55. Doan TB, Eriksson NA, Graham D, Funder JW, Simpson ER, Kuczek ES, et al. 
Breast cancer prognosis predicted by nuclear receptor-coregulator networks. 
Mol Oncol (2014) 8:998–1013. doi:10.1016/j.molonc.2014.03.017 
 56. Knower KC, Chand AL, Eriksson N, Takagi K, Miki Y, Sasano H, et  al. 
Distinct nuclear receptor expression in stroma adjacent to breast tumors. 
Breast Cancer Res Treat (2013) 142:211–23. doi:10.1007/s10549-013-2716-6 
 57. Muscat GE, Eriksson NA, Byth K, Loi S, Graham D, Jindal S, et al. Research 
resource: nuclear receptors as transcriptome: discriminant and prognostic 
value in breast cancer. Mol Endocrinol (2013) 27:350–65. doi:10.1210/
me.2012-1265 
 58. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et  al. 
Molecular portraits of human breast tumours. Nature (2000) 406:747–52. 
doi:10.1038/35021093 
 59. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene 
expression patterns of breast carcinomas distinguish tumor subclasses 
with clinical implications. Proc Natl Acad Sci U S A (2001) 98:10869–74. 
doi:10.1073/pnas.191367098 
 60. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated 
observation of breast tumor subtypes in independent gene expression 
data sets. Proc Natl Acad Sci U S A (2003) 100:8418–23. doi:10.1073/
pnas.0932692100 
 61. van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Bernards R, et al. 
Expression profiling predicts outcome in breast cancer. Breast Cancer Res 
(2003) 5:57–8. doi:10.1186/bcr716 
 62. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A 
gene-expression signature as a predictor of survival in breast cancer. N Engl J 
Med (2002) 347:1999–2009. doi:10.1056/NEJMoa021967 
 63. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, et al. 
FOXA1 expression in breast cancer  –  correlation with luminal subtype A 
and survival. Clin Cancer Res (2007) 13:4415–21. doi:10.1158/1078-0432.
CCR-07-0122 
 64. Camp JT, Elloumi F, Roman-Perez E, Rein J, Stewart DA, Harrell JC, et al. 
Interactions with fibroblasts are distinct in Basal-like and luminal breast can-
cers. Mol Cancer Res (2011) 9:3–13. doi:10.1158/1541-7786.MCR-10-0372 
 65. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, 
HER2 status, and prognosis of patients with luminal B breast cancer. J Natl 
Cancer Inst (2009) 101:736–50. doi:10.1093/jnci/djp082 
 66. Gatza ML, Silva GO, Parker JS, Fan C, Perou CM. An integrated genomics 
approach identifies drivers of proliferation in luminal-subtype human breast 
cancer. Nat Genet (2014) 46(10):1051–9. doi:10.1038/ng.3073 
 67. Gyorffy B, Schafer R. Meta-analysis of gene expression profiles related to 
relapse-free survival in 1,079 breast cancer patients. Breast Cancer Res Treat 
(2009) 118:433–41. doi:10.1007/s10549-008-0242-8 
 68. Madden SF, Clarke C, Gaule P, Aherne ST, O’Donovan N, Clynes M, et al. 
BreastMark: an integrated approach to mining publicly available transcrip-
tomic datasets relating to breast cancer outcome. Breast Cancer Res (2013) 
15:R52. doi:10.1186/bcr3444 
 69. Ning BF, Ding J, Yin C, Zhong W, Wu K, Zeng X, et al. Hepatocyte nuclear 
factor 4 alpha suppresses the development of hepatocellular carcinoma. 
Cancer Res (2010) 70:7640–51. doi:10.1158/0008-5472.CAN-10-0824 
 70. Reznik E, Sander C. Extensive decoupling of metabolic genes in cancer. PLoS 
Comput Biol (2015) 11:e1004176. doi:10.1371/journal.pcbi.1004176 
 71. Kummer MP, Hammerschmidt T, Martinez A, Terwel D, Eichele 
G, Witten A, et  al. Ear2 deletion causes early memory and learning 
deficits in APP/PS1 mice. J Neurosci (2014) 34:8845–54. doi:10.1523/
JNEUROSCI.4027-13.2014 
 72. Liu X, Huang X, Sigmund CD. Identification of a nuclear orphan receptor 
(Ear2) as a negative regulator of renin gene transcription. Circ Res (2003) 
92:1033–40. doi:10.1161/01.RES.0000071355.82009.43 
 73. Warnecke M, Oster H, Revelli JP, Alvarez-Bolado G, Eichele G. Abnormal 
development of the locus coeruleus in Ear2(Nr2f6)-deficient mice impairs 
the functionality of the forebrain clock and affects nociception. Genes Dev 
(2005) 19:614–25. doi:10.1101/gad.317905 
 74. Zhang Y, Dufau ML. EAR2 and EAR3/COUP-TFI regulate transcription 
of the rat LH receptor. Mol Endocrinol (2001) 15:1891–905. doi:10.1210/
mend.15.11.0720 
 75. Yang S, Fang Z, Suzuki T, Sasano H, Zhou J, Gurates B, et  al. Regulation 
of aromatase P450 expression in endometriotic and endometrial stromal 
cells by CCAAT/enhancer binding proteins (C/EBPs): decreased C/EBPbeta 
in endometriosis is associated with overexpression of aromatase. J Clin 
Endocrinol Metab (2002) 87:2336–45. doi:10.1210/jc.87.5.2336 
 76. Gerhart-Hines Z, Feng D, Emmett MJ, Everett LJ, Loro E, Briggs ER, et al. 
The nuclear receptor Rev-erbalpha controls circadian thermogenic plasticity. 
Nature (2013) 503:410–3. doi:10.1038/nature12642 
 77. Kourtidis A, Jain R, Carkner RD, Eifert C, Brosnan MJ, Conklin DS. An RNA 
interference screen identifies metabolic regulators NR1D1 and PBP as novel 
survival factors for breast cancer cells with the ERBB2 signature. Cancer Res 
(2010) 70:1783–92. doi:10.1158/0008-5472.CAN-09-1550 
 78. Hu YC, Shyr CR, Che W, Mu XM, Kim E, Chang C. Suppression of estrogen 
receptor-mediated transcription and cell growth by interaction with TR2 
orphan receptor. J Biol Chem (2002) 277:33571–9. doi:10.1074/jbc.M203531200 
 79. Tanabe O, Shen Y, Liu Q, Campbell AD, Kuroha T, Yamamoto M, et al. The 
TR2 and TR4 orphan nuclear receptors repress Gata1 transcription. Genes 
Dev (2007) 21:2832–44. doi:10.1101/gad.1593307 
 80. Boidot R, Vegran F, Jacob D, Chevrier S, Cadouot M, Feron O, et  al. The 
transcription factor GATA-1 is overexpressed in breast carcinomas and con-
tributes to survivin upregulation via a promoter polymorphism. Oncogene 
(2010) 29:2577–84. doi:10.1038/onc.2009.525 
 81. Suzuki T, Kasahara M, Yoshioka H, Umesono K, Morohashi K. LXXLL motifs 
in Dax-1 have target specificity for the orphan nuclear receptors Ad4BP/SF-1 
and LRH-1. Endocr Res (2002) 28:537. doi:10.1081/ERC-120016835 
 82. Yazawa T, Inaoka Y, Okada R, Mizutani T, Yamazaki Y, Usami Y, et al. PPAR-
gamma coactivator-1alpha regulates progesterone production in ovarian 
granulosa cells with SF-1 and LRH-1. Mol Endocrinol (2010) 24:485–96. 
doi:10.1210/me.2009-0352 
 83. Li Y, Choi M, Suino K, Kovach A, Daugherty J, Kliewer SA, et al. Structural 
and biochemical basis for selective repression of the orphan nuclear receptor 
liver receptor homolog 1 by small heterodimer partner. Proc Natl Acad Sci U 
S A (2005) 102:9505–10. doi:10.1073/pnas.0501204102 
 84. Whitby RJ, Dixon S, Maloney PR, Delerive P, Goodwin BJ, Parks DJ, et al. 
Identification of small molecule agonists of the orphan nuclear receptors 
liver receptor homolog-1 and steroidogenic factor-1. J Med Chem (2006) 
49:6652–5. doi:10.1021/jm060990k 
 85. Benod C, Carlsson J, Uthayaruban R, Hwang P, Irwin JJ, Doak AK, et  al. 
Structure-based discovery of antagonists of nuclear receptor LRH-1. J Biol 
Chem (2013) 288:19830–44. doi:10.1074/jbc.M112.411686 
 86. Lazarus KA, Wijayakumara D, Chand AL, Simpson ER, Clyne CD. 
Therapeutic potential of liver receptor homolog-1 modulators. J Steroid 
Biochem Mol Biol (2012) 130:138–46. doi:10.1016/j.jsbmb.2011.12.017 
 87. Bouchard MF, Taniguchi H, Viger RS. Protein kinase A-dependent synergism 
between GATA factors and the nuclear receptor, liver receptor homolog-1, 
regulates human aromatase (CYP19) PII promoter activity in breast cancer 
cells. Endocrinology (2005) 146:4905–16. doi:10.1210/en.2005-0187 
 88. Clyne CD, Kovacic A, Speed CJ, Zhou J, Pezzi V, Simpson ER. Regulation of 
aromatase expression by the nuclear receptor LRH-1 in adipose tissue. Mol 
Cell Endocrinol (2004) 215:39–44. doi:10.1016/j.mce.2003.11.001 
August 2015 | Volume 6 | Article 11510
Aesoy et al. Orphan nuclear receptors and breast cancer
Frontiers in Endocrinology | www.frontiersin.org
 89. Clyne CD, Speed CJ, Zhou J, Simpson ER. Liver receptor homologue-1 (LRH-
1) regulates expression of aromatase in preadipocytes. J Biol Chem (2002) 
277:20591–7. doi:10.1074/jbc.M201117200 
 90. Annicotte JS, Chavey C, Servant N, Teyssier J, Bardin A, Licznar A, et al. The 
nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene. 
Oncogene (2005) 24(55):8167–75. doi:10.1038/sj.onc.1208950 
 91. Bianco S, Brunelle M, Jangal M, Magnani L, Gevry N. LRH-1 governs vital 
transcriptional programs in endocrine-sensitive and -resistant breast cancer 
cells. Cancer Res (2014) 74:2015–25. doi:10.1158/0008-5472.CAN-13-2351 
 92. Chand AL, Wijayakumara DD, Knower KC, Herridge KA, Howard TL, 
Lazarus KA, et al. The orphan nuclear receptor LRH-1 and ERalpha activate 
GREB1 expression to induce breast cancer cell proliferation. PLoS One (2012) 
7:e31593. doi:10.1371/journal.pone.0031593 
 93. Lai CF, Flach KD, Alexi X, Fox SP, Ottaviani S, Thiruchelvam PT, et  al. 
Co-regulated gene expression by oestrogen receptor alpha and liver receptor 
homolog-1 is a feature of the oestrogen response in breast cancer cells. 
Nucleic Acids Res (2013) 41:10228–40. doi:10.1093/nar/gkt827 
 94. Thiruchelvam PT, Lai CF, Hua H, Thomas RS, Hurtado A, Hudson W, et al. 
The liver receptor homolog-1 regulates estrogen receptor expression in 
breast cancer cells. Breast Cancer Res Treat (2011) 127:385–96. doi:10.1007/
s10549-010-0994-9 
 95. Miki Y, Clyne CD, Suzuki T, Moriya T, Shibuya R, Nakamura Y, et  al. 
Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast 
carcinoma: possible regulator of insitu steroidogenesis. Cancer Lett (2006) 
244:24–33. doi:10.1016/j.canlet.2005.11.038 
 96. Chand AL, Herridge KA, Thompson EW, Clyne CD. The orphan nuclear 
receptor LRH-1 promotes breast cancer motility and invasion. Endocr Relat 
Cancer (2010) 17:965–75. doi:10.1677/ERC-10-0179 
 97. Lazarus KA, Zhao Z, Knower KC, To SQ, Chand AL, Clyne CD. Oestradiol 
reduces liver receptor homolog-1 mRNA transcript stability in breast cancer 
cell lines. Biochem Biophys Res Commun (2013) 438:533–9. doi:10.1016/j.
bbrc.2013.07.101 
 98. Chand AL, Herridge KA, Howard TL, Simpson ER, Clyne CD. Tissue-specific 
regulation of aromatase promoter II by the orphan nuclear receptor LRH-1 
in breast adipose stromal fibroblasts. Steroids (2011) 76:741–4. doi:10.1016/j.
steroids.2011.02.024 
 99. Ariazi EA, Kraus RJ, Farrell ML, Jordan VC, Mertz JE. Estrogen-related 
receptor alpha1 transcriptional activities are regulated in part via the ErbB2/
HER2 signaling pathway. Mol Cancer Res (2007) 5:71–85. doi:10.1158/1541-
7786.MCR-06-0227 
 100. Gerdin AK, Surve VV, Jonsson M, Bjursell M, Bjorkman M, Edenro A, 
et  al. Phenotypic screening of hepatocyte nuclear factor (HNF) 4-gamma 
receptor knockout mice. Biochem Biophys Res Commun (2006) 349:825–32. 
doi:10.1016/j.bbrc.2006.08.103 
 101. Deblois G, Chahrour G, Perry MC, Sylvain-Drolet G, Muller WJ, Giguere V. 
Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta 
promotes mammary gland tumorigenesis. Cancer Res (2010) 70:10277–87. 
doi:10.1158/0008-5472.CAN-10-2840 
 102. Deblois G, Hall JA, Perry MC, Laganiere J, Ghahremani M, Park M, et al. 
Genome-wide identification of direct target genes implicates estrogen-re-
lated receptor alpha as a determinant of breast cancer heterogeneity. Cancer 
Res (2009) 69:6149–57. doi:10.1158/0008-5472.CAN-09-1251 
 103. Law SW, Conneely OM, DeMayo FJ, O’Malley BW. Identification of a 
new brain-specific transcription factor, NURR1. Mol Endocrinol (1992) 
6:2129–35. doi:10.1210/mend.6.12.1491694 
 104. Milbrandt J. Nerve growth factor induces a gene homologous to the glucocorti-
coid receptor gene. Neuron (1988) 1:183–8. doi:10.1016/0896-6273(88)90138-9 
 105. Ohkura N, Hijikuro M, Yamamoto A, Miki K. Molecular cloning of a novel 
thyroid/steroid receptor superfamily gene from cultured rat neuronal cells. 
Biochem Biophys Res Commun (1994) 205:1959–65. doi:10.1006/bbrc.1994.2900 
 106. Deutsch AJ, Angerer H, Fuchs TE, Neumeister P. The nuclear orphan recep-
tors NR4A as therapeutic target in cancer therapy. Anticancer Agents Med 
Chem (2012) 12:1001–14. doi:10.2174/187152012803529619 
 107. Llopis S, Singleton B, Duplessis T, Carrier L, Rowan B, Williams C. 
Dichotomous roles for the orphan nuclear receptor NURR1 in breast cancer. 
BMC Cancer (2013) 13:139. doi:10.1186/1471-2407-13-139 
 108. Inamoto T, Czerniak BA, Dinney CP, Kamat AM. Cytoplasmic mislocaliza-
tion of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder 
cancer. Cancer (2010) 116:340–6. doi:10.1002/cncr.24737 
 109. Ohkubo T, Ohkura N, Maruyama K, Sasaki K, Nagasaki K, Hanzawa H, et al. 
Early induction of the orphan nuclear receptor NOR-1 during cell death 
of the human breast cancer cell line MCF-7. Mol Cell Endocrinol (2000) 
162:151–6. doi:10.1016/S0303-7207(00)00222-7 
 110. Forman BM, Umesono K, Chen J, Evans RM. Unique response pathways are 
established by allosteric interactions among nuclear hormone receptors. Cell 
(1995) 81:541–50. doi:10.1016/0092-8674(95)90075-6 
 111. Perlmann T, Jansson L. A novel pathway for vitamin A signaling mediated 
by RXR heterodimerization with NGFI-B and NURR1. Genes Dev (1995) 
9:769–82. doi:10.1101/gad.9.7.769 
 112. Maruyama K, Tsukada T, Bandoh S, Sasaki K, Ohkura N, Yamaguchi K. 
Retinoic acids differentially regulate NOR-1 and its closely related orphan 
nuclear receptor genes in breast cancer cell line MCF-7. Biochem Biophys Res 
Commun (1997) 231:417–20. doi:10.1006/bbrc.1997.6122 
 113. Lacroix A, Lippman ME. Binding of retinoids to human breast cancer 
cell lines and their effects on cell growth. J Clin Invest (1980) 65:586–91. 
doi:10.1172/JCI109703 
 114. Rubin M, Fenig E, Rosenauer A, Menendez-Botet C, Achkar C, Bentel 
JM, et  al. 9-Cis retinoic acid inhibits growth of breast cancer cells and 
down-regulates estrogen receptor RNA and protein. Cancer Res (1994) 
54:6549–56. 
 115. van der Burg B, van der Leede BM, Kwakkenbos-Isbrucker L, Salverda S, de 
Laat SW, van der Saag PT. Retinoic acid resistance of estradiol-independent 
breast cancer cells coincides with diminished retinoic acid receptor function. 
Mol Cell Endocrinol (1993) 91:149–57. doi:10.1016/0303-7207(93)90267-N 
 116. Le Dily F, Metivier R, Gueguen MM, Le Peron C, Flouriot G, Tas P, et al. 
COUP-TFI modulates estrogen signaling and influences proliferation, 
survival and migration of breast cancer cells. Breast Cancer Res Treat (2008) 
110:69–83. doi:10.1007/s10549-007-9693-6 
 117. Nagasaki S, Suzuki T, Miki Y, Akahira J, Shibata H, Ishida T, et  al. 
Chicken ovalbumin upstream promoter transcription factor II in human 
breast carcinoma: possible regulator of lymphangiogenesis via vascular 
endothelial growth factor-C expression. Cancer Sci (2009) 100:639–45. 
doi:10.1111/j.1349-7006.2008.01078.x 
 118. Metivier R, Gay FA, Hubner MR, Flouriot G, Salbert G, Gannon F, et  al. 
Formation of an hER alpha-COUP-TFI complex enhances hER alpha AF-1 
through Ser118 phosphorylation by MAPK. EMBO J (2002) 21:3443–53. 
doi:10.1093/emboj/cdf344 
 119. Boudot A, Kerdivel G, Lecomte S, Flouriot G, Desille M, Godey F, et  al. 
COUP-TFI modifies CXCL12 and CXCR4 expression by activating EGF 
signaling and stimulates breast cancer cell migration. BMC Cancer (2014) 
14:407. doi:10.1186/1471-2407-14-407 
 120. Johansson L, Thomsen JS, Damdimopoulos AE, Spyrou G, Gustafsson JA, 
Treuter E. The orphan nuclear receptor SHP inhibits agonist-dependent 
transcriptional activity of estrogen receptors ERalpha and ERbeta. J Biol 
Chem (1999) 274:345–53. doi:10.1074/jbc.274.1.345 
 121. Kovacic A, Speed CJ, Simpson ER, Clyne CD. Inhibition of aromatase 
transcription via promoter II by short heterodimer partner in human pread-
ipocytes. Mol Endocrinol (2004) 18:252–9. doi:10.1210/me.2003-0211 
 122. Sengupta D, Bhargava DK, Dixit A, Sahoo BS, Biswas S, Biswas G, et  al. 
ERRbeta signalling through FST and BCAS2 inhibits cellular proliferation in 
breast cancer cells. Br J Cancer (2014) 110:2144–58. doi:10.1038/bjc.2014.53 
 123. Giguere V. Orphan nuclear receptors: from gene to function. Endocr Rev 
(1999) 20:689–725. doi:10.1210/edrv.20.5.0378 
 124. Lu D, Kiriyama Y, Lee KY, Giguere V. Transcriptional regulation of the estro-
gen-inducible pS2 breast cancer marker gene by the ERR family of orphan 
nuclear receptors. Cancer Res (2001) 61(18):6755–61. 
 125. Tanida T, Matsuda KI, Yamada S, Hashimoto T, Kawata M. Estrogen-related 
receptor beta reduces the subnuclear mobility of estrogen receptor alpha 
and suppresses estrogen-dependent cellular function. J Biol Chem (2015) 
290:12332–45. doi:10.1074/jbc.M114.619098 
 126. Chen F, Cooney AJ, Wang Y, Law SW, O’Malley BW. Cloning of a novel 
orphan receptor (GCNF) expressed during germ cell development. Mol 
Endocrinol (1994) 8:1434–44. doi:10.1210/me.8.10.1434 
 127. Wang Q, Cooney AJ. Revisiting the role of GCNF in embryonic 
development. Semin Cell Dev Biol (2013) 24:679–86. doi:10.1016/j.
semcdb.2013.08.003 
 128. Lan ZJ, Gu P, Xu X, Jackson KJ, DeMayo FJ, O’Malley BW, et al. GCNF-
dependent repression of BMP-15 and GDF-9 mediates gamete regulation 
August 2015 | Volume 6 | Article 11511
Aesoy et al. Orphan nuclear receptors and breast cancer
Frontiers in Endocrinology | www.frontiersin.org
of female fertility. EMBO J (2003) 22:4070–81. doi:10.1093/emboj/
cdg405 
 129. Willis S, De P, Dey N, Long B, Young B, Sparano JA, et  al. Enriched 
transcription factor signatures in triple negative breast cancer indicates 
possible targeted therapies with existing drugs. Meta Gene (2015) 4:129–41. 
doi:10.1016/j.mgene.2015.04.002 
 130. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et  al. An 
online survival analysis tool to rapidly assess the effect of 22,277 genes on 
breast cancer prognosis using microarray data of 1,809 patients. Breast 
Cancer Res Treat (2010) 123:725–31. doi:10.1007/s10549-009-0674-9 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2015 Aesoy, Clyne and Chand. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) or licensor are credited and that the original publication in this journal 
is cited, in accordance with accepted academic practice. No use, distribution or 
reproduction is permitted which does not comply with these terms.
